Healthcare provider profile · identity verified

David James Springer, M.D.

Family Practice · ROCK RAPIDS, IA · NPI 1649353681

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	222	53
Levothyroxine Sodium	Levothyroxine Sodium	189	33
Gabapentin	Gabapentin	188	34
Lisinopril	Lisinopril	181	47
Rosuvastatin Calcium	Rosuvastatin Calcium	172	48
Metoprolol Succinate	Metoprolol Succinate	157	36
Losartan Potassium	Losartan Potassium	137	33
Amlodipine Besylate	Amlodipine Besylate	132	38
Metformin Hcl	Metformin Hcl	125	26
Omeprazole	Omeprazole	124	29
Tamsulosin Hcl	Tamsulosin Hcl	123	34
Sertraline Hcl	Sertraline Hcl	100	21
Furosemide	Furosemide	92	31
Pantoprazole Sodium	Pantoprazole Sodium	84	23
Meloxicam	Meloxicam	80	26
Jantoven	Warfarin Sodium	73	suppressed
Alendronate Sodium	Alendronate Sodium	70	16
Eliquis	Apixaban	69	13
Clopidogrel	Clopidogrel Bisulfate	66	13
Metoprolol Tartrate	Metoprolol Tartrate	61	17
Simvastatin	Simvastatin	61	18
Donepezil Hcl	Donepezil Hcl	60	suppressed
Xarelto	Rivaroxaban	60	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	58	12
Duloxetine Hcl	Duloxetine Hcl	58	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	57	15
Tramadol Hcl	Tramadol Hcl	55	22
Carvedilol	Carvedilol	53	12
Potassium Chloride	Potassium Chloride	53	15
Lorazepam	Lorazepam	48	16
Mirtazapine	Mirtazapine	46	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	46	suppressed
Prednisone	Prednisone	46	42
Cefdinir	Cefdinir	43	41
Dexlansoprazole Dr	Dexlansoprazole	43	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	43	20
Montelukast Sodium	Montelukast Sodium	43	suppressed
Allopurinol	Allopurinol	42	suppressed
Famotidine	Famotidine	39	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	39	suppressed
Digoxin	Digoxin	38	suppressed
Bumetanide	Bumetanide	36	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	35	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	35	suppressed
Finasteride	Finasteride	35	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	34	suppressed
Ropinirole Hcl	Ropinirole Hcl	31	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Vraylar	Cariprazine Hcl	29	suppressed
Metformin Hcl Er	Metformin Hcl	28	suppressed
Breo Ellipta	Fluticasone/Vilanterol	27	suppressed
Clozapine	Clozapine	27	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	25	suppressed
Glipizide Er	Glipizide	25	suppressed
Ozempic	Semaglutide	25	suppressed
Sucralfate	Sucralfate	25	suppressed
Synthroid	Levothyroxine Sodium	25	suppressed
Chlorthalidone	Chlorthalidone	24	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Fluticasone Propionate	Fluticasone Propionate	21	suppressed
Glimepiride	Glimepiride	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	18	11
Benazepril Hcl	Benazepril Hcl	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Raloxifene Hcl	Raloxifene Hcl	17	suppressed
Trazodone Hcl	Trazodone Hcl	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	12
Baclofen	Baclofen	16	suppressed
Indapamide	Indapamide	16	suppressed
Lansoprazole	Lansoprazole	16	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	16
Triamcinolone Acetonide	Triamcinolone Acetonide	16	13
Arnuity Ellipta	Fluticasone Furoate	15	suppressed
Bupropion Hcl	Bupropion Hcl	15	suppressed
Glipizide	Glipizide	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Jardiance	Empagliflozin	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	13
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Restasis	Cyclosporine	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Topiramate	Topiramate	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Azithromycin	Azithromycin	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Flecainide Acetate	Flecainide Acetate	12	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	12	suppressed
Methylprednisolone	Methylprednisolone	12	12
Bevespi Aerosphere	Glycopyrrolate/Formoterol Fum	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Humira Pen	Adalimumab	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Metolazone	Metolazone	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error